Efficacy Of BCG For Prevention Of Recurrence Of Recurred Non-muscle Invasive Bladder Cancer

Background and purpose:Non-muscle invasive bladder cancer is one of the common malignant tumors of the genitourinary system,accounting for about 75% of primary bladder cancer.If it is not detected early and treatment is taken,it often progresses quickly.The prognosis is poor.The primary treatment for early non-muscle invasive bladder cancer is transurethral resection of the bladder tumor(TURBT).However,non-muscle invasive bladder cancer has a high recurrence rate after operation.Therefore,the antitumor drug bladder perfusion is usually used as an auxiliary method to reduce the recurrence rate.Regular cystoscopy is performed to check for tumor recurrence.Despite the standard treatment,some patients still relapse within one year after the first onset.Due to regular cystoscopy,these patients can often be detected early in the course of the disease.For patients with second-onset non-muscle invasive bladder cancer,medical treatment after surgical resection is particularly important.At present,the efficacy of bacillus Calmette-Guerin(BCG)bladder infusion to prevent the recurrence of non-muscle invasive bladder cancer has been widely recognized.Both the American Urological Association and the European Urological Society recommend BCG as a non-muscle invasive bladder.Postoperative treatment of cancer,other common bladder infusion drugs are gemcitabine,epirubicin and so on.However,currently there is insufficient clinical data to support the effectiveness of BCG in preventing recurrence of postoperative perfusion in patients with recurrent non-muscle invasive bladder cancer.In this study,patients with recurrent non-muscle invasive bladder cancer were regularly followed up after surgery to collect data on the efficacy of BCG to prevent tumor recurrence and other drugs to prevent recurrence.Retrospective analysis of BCG in preventing recurrent non-muscle invasive bladder cancer The efficacy of recurrence after second resection,to understand the effect of BCG on the prognosis of patients with recurrent non-muscle invasive bladder cancer,and to provide a theoretical basis for the selection of postoperative treatment strategies for patients with recurrent non-muscle invasive bladder cancer.Methods:Patients with newly diagnosed non-muscle invasive bladder cancer diagnosed after cystoscopy and MRI were collected in our hospital from January 2016 to January2019.Cystoscopy tumor resection and postoperative histological examination were performed.Confirmed non-muscle invasive bladder cancer,postoperatively performed anti-tumor drug bladder lavage and regularly underwent cystoscopy,and found bladder tumor lesions within 1 year after the first resection.A total of 61 patients diagnosed with non-muscle invasive bladder cancer were examined,and the clinical data(including gender,age,smoking history,family history of tumor,clinical stage,pathological type,etc.)of the patients were counted.According to the secondary bladder tumor The drugs selected after resection were divided into the experimental group(BCG group)and the control group,with regular follow-up.The clinical data of the patients were analyzed,and the clinical characteristics of the two groups of patients were compared.The tumor recurrence after the second resection was used as the endpoint event.All data were processed using the IBM SPSS 22.0statistical software,and all were normally distributed.The measurement data are expressed in the form of mean ± standard deviation.The comparison of the mean of the measurement data is by t test,and the count data is applied by X2 test.The gender,age,smoking history,family history of tumor,clinical stage,and pathological type of the two groups are analyzed,BCG perfusion,adverse reactions and curative effects after treatment.P <0.05 was considered statistically significant.Result:1.A total of 61 patients with recurrent non-muscular invasive bladder cancer were included in this study.Among them,32 patients in the experimental group using BCG for bladder perfusion after resection,and control group patients using other antitumor drugs for bladder perfusion For 29 cases.There were no significant differences in gender,age,history of no smoking,family history of tumor,clinical stage,or case type between the two groups,and there were no statistical differences in these clinical characteristics between the two groups(P> 0.05).2.In the test group,11 patients had urinary frequency,urgency,dysuria,hematuria and other adverse reactions within one year after the second resection(incidence rate was 34.4%),and 6 patients in the control group had adverse reactions(incidence rate was 20.7 %).3.There were 4 cases of recurrence within one year after the second point resection in the test group(recurrence rate of 12.5%),and 6 cases of recurrence within the year after the second resection in the control group(recurrence rate of 20.7%).Conclusion:1.Compared with gemcitabine,the use of BCG to prevent recurrence after resection of patients with recurrent non-muscle invasive bladder cancer has a higher probability of adverse reactions,but fewer serious adverse reactions,so BCG is relatively safe.2.Compared with other drugs,bladder perfusion using BCG after the second resection can have a better effect.